MAIA Biotechnology Crecimiento futuro

Future controles de criterios 0/6

Se prevé un crecimiento anual de los beneficios y los ingresos de MAIA Biotechnology de 3.5% y 155.1% respectivamente, mientras que el BPA disminuirá en un 2.8% al año.

Información clave

3.5%

Tasa de crecimiento de los beneficios

-2.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	28.3%
Tasa de crecimiento de los ingresos	155.1%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	14 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Previsiones de crecimiento de beneficios e ingresos

NYSEAM:MAIA - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	65	-22	N/A	N/A	1
12/31/2025	N/A	-41	N/A	N/A	1
12/31/2024	N/A	-30	N/A	N/A	2
9/30/2024	N/A	-26	-16	-16	N/A
6/30/2024	N/A	-28	-15	-15	N/A
3/31/2024	N/A	-24	-13	-13	N/A
12/31/2023	N/A	-20	-13	-13	N/A
9/30/2023	N/A	-18	-12	-12	N/A
6/30/2023	N/A	-18	-13	-13	N/A
3/31/2023	N/A	-16	-13	-13	N/A
12/31/2022	N/A	-16	-12	-12	N/A
9/30/2022	N/A	-15	-11	-11	N/A
6/30/2022	N/A	-15	-8	-8	N/A
3/31/2022	N/A	-15	-7	-7	N/A
12/31/2021	N/A	-13	-4	-4	N/A
9/30/2021	N/A	-13	-3	-3	N/A
12/31/2020	N/A	-7	-2	-2	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que MAIA siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que MAIA siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que MAIA siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que MAIA no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que MAIA no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de MAIA se prevé que sea elevada dentro de 3 años.

MAIA Biotechnology Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

MAIA Biotechnology, Inc. announced that it expects to receive $2.439232 million in funding

MAIA Biotechnology, Inc. to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference

New major risk - Financial position

Maia Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent

Maia Biotechnology Reveals New Clinical Data Showing Thio’s Strong Efficacy in Non-Small Cell Lung Cancer

New major risk - Share price stability

MAIA Biotechnology, Inc. announced a financing transaction

MAIA Biotechnology, Inc. announced that it expects to receive $0.664994 million in funding

MAIA Biotechnology, Inc., Annual General Meeting, May 24, 2024

MAIA Biotechnology, Inc. announced that it expects to receive $1.327985 million in funding

MAIA Biotechnology, Inc. Appoints Saadettin Kilickap to its Scientific Advisory Board

MAIA Biotechnology, Inc. Announces Positive Efficacy Data for Third-Line Treatment in its Phase 2 THIO-101 Clinical Trial Evaluating THIO Sequenced with CPI Cemiplimab in Advanced NSCLC

MAIA Biotechnology, Inc. Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. has filed a Follow-on Equity Offering in the amount of $1.445 million.

MAIA Biotechnology, Inc. Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer

Maia Biotechnology, Inc. Announces Publication of International Pct Patent Application Covering Anticancer Telomere-Targeting Compounds

MAIA Biotechnology, Inc. Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024

MAIA Biotechnology, Inc. Announces Dose Selection in Thio-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

New major risk - Shareholder dilution

NYSE American Believes MAIA Biotechnology Not in Compliance with Listing Standards

MAIA Biotechnology, Inc. Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial

MAIA Biotechnology, Inc. Reveals New Data Showing THIO's Potent Anticancer Activity in Aggressive Pediatric Brain Cancer

MAIA Biotechnology, Inc. Announces Potent Anticancer Activity of THIO in Gliomas

MAIA Biotechnology, Inc. Announces FDA Clearance of IND Application for THIO, a First-in-Class Telomere Targeting Agent for the Treatment of Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. (NYSEAM:MAIA) announces an Equity Buyback for $0.8 million worth of its shares.

New major risk - Revenue and earnings growth

MAIA Biotechnology, Inc. Provides Updates for THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. Reports Updates on Preliminary Survival Data for Thio-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. Files Second Patent for New Telomere-Targeting Molecules Program

Lead Independent Director recently bought US$300k worth of stock

MAIA Biotechnology, Inc. Announces it Intends to Initiate its Second Phase 2 Go-To-Market Trial Evaluating THIO

MAIA Biotechnology, Inc. Holds Successful Pre-IND Meeting with FDA for Planned US Expansion of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. Expands Phase 2 THIO-101 Trial to Europe

High number of new and inexperienced directors

MAIA Biotechnology, Inc. has completed an IPO in the amount of $10 million.

High number of new and inexperienced directors

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento